---
title: "Rundu Pharma: Net loss of 36.1931 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255221911.md"
description: "Rundu Pharma announced that its operating revenue in the first half of 2025 was CNY 548 million, a year-on-year decrease of 8.22%. The net profit attributable to shareholders of the listed company was -CNY 36.1931 million, a year-on-year decrease of 195.75%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves"
datetime: "2025-08-29T13:24:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255221911.md)
  - [en](https://longbridge.com/en/news/255221911.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255221911.md)
generator: "portal-rs"
---

# Rundu Pharma: Net loss of 36.1931 million yuan in the first half of 2025

Rundu Pharma announced that its operating revenue in the first half of 2025 was 548 million yuan, a year-on-year decrease of 8.22%. The net profit attributable to shareholders of the listed company was -36.1931 million yuan, a year-on-year decrease of 195.75%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to increase capital through reserves

### Related Stocks

- [002923.CN](https://longbridge.com/en/quote/002923.CN.md)

## Related News & Research

- [REG - Windar Photonics PLC - Result of Placing & Direct Subscription](https://longbridge.com/en/news/296816414.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [Volcanic Gold Mines secures first refusal rights on Los Angeles antimony mine in Guatemala](https://longbridge.com/en/news/296776469.md)
- [Cheng Shin Rubber: 2026H1 net income surged 43.8% year-over-year, driven by higher revenue and improved margins](https://longbridge.com/en/news/296745040.md)
- [AL Sydbank A/S share buyback programme: transactions in week 34](https://longbridge.com/en/news/296759170.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**